Transgene Biotek has informed that the trading window for dealing in the securities of the Company will remain closed from 01.04.2025 till 48 hours after the declaration of financial results for the quarter and year ended 31.03.2025, for all designated persons, their immediate relatives and all connected persons covered under the Company’s Code of Conduct. The date of meeting of the Board of Directors to approve the Audited Financial results of the Company for the quarter and year ended March 31, 2025 will be informed in due course.
The above information is a part of company’s filings submitted to BSE.
